NASDAQ · Financial Statements
Lunai Bioworks Inc. (RENB) Financial Statements
$1.42
NASDAQ: RENB
Market Cap $32.92M
Overview Financials Dividend
Lunai Bioworks Inc. most recently reported annual revenue of $0, a net loss of $178.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025
Revenue $0 $0 $0 $0 $0 Operating Profit $-23.0M $-116.0M $-39.0M $-82.0M $-189.0M Net Profit $-27.0M $-113.0M $-40.0M $-81.0M $-178.0M EPS $-5.70 $-21.60 $-7.10 $-8.40 $-1.08 Op Margin — — — — —
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025
Total Assets $190.0M $85.0M $58.0M $163.0M $8.0M Total Liabilities $15.0M $12.0M $12.0M $31.0M $30.0M Cash $21.0M $9.0M $2.0M $0 $0 Borrowings $7.0M $7.0M $6.0M $4.0M $10.0M
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow $-21.0M $-16.0M $-12.0M $-11.0M $-8.0M Investing Cash Flow $0 $0 $0 $-1.0M $0 Financing Cash Flow $0 $0 $2.0M $-1.0M $-1.0M Net Cash Flow $12.0M $-11.0M $-7.0M $-2.0M $0 Free Cash Flow $-21.0M $-16.0M $-12.0M $-11.0M $-8.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.00 EV / EBITDA -0.23 FCF Yield -15.98% Quick Ratio 0.19 Interest Coverage 814.53 Return 1Y — Return 3Y — Return 5Y —
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .